Neutralizing IL-38 activates γδ T cell-dependent antitumor immunity and sensitizes for chemotherapy.
Priscila da SilvaJavier MoraXin YouSvenja WiechmannMateusz PutyrskiJavier Garcia-PardoAimo KanntAndreas ErnstBernhard BrueneAndreas WeigertPublished in: Journal for immunotherapy of cancer (2024)
These data suggest that interfering with IL-38 improves antitumor immunity even in immunologically cold tumors.